ClinicalTrials.gg
CompletedNCT02651714Updated Jun 13, 2024Results posted

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

A Phase 2 interventional study of Tradipitant and Placebo in Atopic Dermatitis, sponsored by Vanda Pharmaceuticals. Completed at 28 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
196th of 544
168 · median 96
Started
2016
with 25 others
Phase 2
202 of 639
18 open now
Registered
180th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 196th largest by enrollment of the 544 interventional ones that give a count, is one of 26 that started in 2016, is one of 202 in phase 2, and was the 180th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • chronic pruritus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and non-pregnant, non-lactating female subjects aged 18 - 65 years (inclusive)
  • Diagnosed with atopic dermatitis
  • Suffering from chronic pruritus with pruritus being actively present

Exclusion criteria

Exclusion Criteria:

  • Chronic pruritus due to condition other than atopic dermatitis (AD)
  • Participation in a previous tradipitant (LY686017 or VLY-686) trial
  • Anyone affiliated with the site or sponsor and/or anyone who may consent under duress
  • Any other sound medical reason as determined by the Investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound study results
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Tradipitant

    Oral

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Oral

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score

    Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left endpoint was marked "no itch" (0 mm) and in the right endpoint was marked "worst imaginable itch" (100 mm).

    Time frame: 56 days

07

Results

Posted Jun 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneTradipitantPlacebo
Started8484
Completed5956
Not completed2528

Outcome measures

PrimaryMean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score

Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left endpoint was marked "no itch" (0 mm) and in the right endpoint was marked "worst imaginable itch" (100 mm).

Time frame:
56 days
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score
score on a scaleTradipitantPlacebo
Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score-41.5 ± 3.89-35.8 ± 4.03

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent through study completion (approximately 100 days) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant0/83 (0%)0/83 (0%)4/83 (4.8%)
Placebo0/82 (0%)0/82 (0%)9/82 (11%)
Most frequent other events
Most frequent other events
EventTradipitantPlacebo
Dermatitis atopicSkin and subcutaneous tissue disorders4/839/82

Baseline characteristics

Age, Continuous
Age, Continuous(years)TradipitantPlaceboTotal
Mean41.05 ± 13.13939.13 ± 13.56840.09 ± 13.350
Sex: Female, Male
Sex: Female, Male(Participants)TradipitantPlaceboTotal
Female5253105
Male323163
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TradipitantPlaceboTotal
Hispanic or Latino232144
Not Hispanic or Latino6163124
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TradipitantPlaceboTotal
White4957106
Black or African American241842
Asian6511
American Indian or Alaska Native011
Native Hawaiian or Other Pacific Islander202
Other336
Region of Enrollment
Region of Enrollment(Participants)TradipitantPlaceboTotal
United States8484168
Average Pruritus VAS at Baseline
Average Pruritus VAS at Baseline(mm)TradipitantPlaceboTotal
Mean81.3 ± 10.7880.3 ± 8.6880.8 ± 9.77
08

Study locations

28 sites
  • Vanda Investigational Site
    Encinitas, California 92024, United States
  • Vanda Investigational Site
    Encino, California 91436, United States
  • Vanda Investigational Site
    Lomita, California 90717, United States
  • Vanda Investigational Site
    San Diego, California 92122, United States
  • Vanda Investigational Site
    San Diego, California 92123, United States
  • Vanda Investigational Site
    Miami, Florida 33126, United States
  • Vanda Investigational Site
    Miami, Florida 33136, United States
  • Vanda Investigational Site
    Ormond Beach, Florida 32174, United States
  • Vanda Investigational Site
    Columbus, Georgia 31904, United States
  • Vanda Investigational Site
    Plainfield, Indiana 46168, United States
  • Vanda Investigational Site
    Crowley, Louisiana 70526, United States
  • Vanda Investigational Site
    Saint Louis, Missouri 63110, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89119, United States
  • Vanda Investigational Site
    New York, New York 10022, United States
  • Vanda Investigational Site
    New York, New York 10075, United States
  • Vanda Investigational Site
    High Point, North Carolina 27262, United States
  • Vanda Investigational Site
    Wilmington, North Carolina 28405, United States
  • Vanda Investigational Site
    Winston-Salem, North Carolina 27104, United States
  • Vanda Investigational Site
    Portland, Oregon 97239, United States
  • Vanda Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Vanda Investigational Site
    Johnston, Rhode Island 02919, United States
  • Vanda Investigational Site
    Charleston, South Carolina 29407, United States
  • Vanda Investigational Site
    Houston, Texas 77030, United States
  • Vanda Investigational Site
    Pflugerville, Texas 78660, United States
  • Vanda Investigational Site
    San Antonio, Texas 78218, United States
  • Vanda Investigational Site
    West Jordan, Utah 84088, United States
  • Vanda Investigational Site
    Seattle, Washington 98101, United States
  • Vanda Investigational Site
    Spokane, Washington 99202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Aug 2017, 18 months.

Results were first posted in Jun 2024, 6 years 10 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 18 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2016
First posted
Jan 11, 2016
StartActual
Jan 19, 2016
Primary completionActual
Aug 4, 2017
CompletionActual
Aug 4, 2017
Results first posted
Jun 13, 2024
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02651714
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Jan 19, 2016
Primary completion
Aug 4, 2017
Completion
Aug 4, 2017
Results posted
Jun 13, 2024
Last update
Jun 13, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion